Skip to main content
. Author manuscript; available in PMC: 2017 May 15.
Published in final edited form as: Clin Cancer Res. 2015 Dec 16;22(10):2351–2358. doi: 10.1158/1078-0432.CCR-15-2013

Figure. 3. The CD74-ROS1D2033N mutation confers crizotinib resistance but remains sensitive to cabozantinib.

Figure. 3

A. Cell growth and viability of Ba/F3 cells expressing native CD74-ROS1 or CD74-ROS1D2033N after 72 h exposure to crizotinib and cabozantinib. Results are shown as mean viability normalized to vehicle-treated control ± SEM (n = 4). Concentrations that decreased cell viability by 50 or 90% are listed as IC50 and IC90, respectively. B. Immunoblot analysis of ROS1, ERK1/2, SHP2, STAT3 and AKT phosphorylation from Ba/F3 CD74-ROS1 and CD74-ROS1D2033N cells after treatment with the indicated concentrations of crizotinib and cabozantinib. GAPDH expression is included as a loading control.